L Kuehlewein1, S R Sadda1, D Sarraf2. 1. 1] Doheny Eye Institute, Los Angeles, CA, USA [2] Stein Eye Institute, Los Angeles, CA, USA. 2. 1] Stein Eye Institute, Los Angeles, CA, USA [2] Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA [3] Greater Los Angeles VA Healthcare Center, Los Angeles, CA, USA.
Abstract
PURPOSE: To study the precise structural aspects of a type 2 neovascular membrane in a patient with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography and perform sequential quantitative analysis of the membrane after ranibizumab therapy. PATIENTS AND METHODS: Split-spectrum amplitude-decorrelation (SSADA) OCT angiography macular cubes (3 × 3 mm) were acquired with a light source centered at 840 nm, a bandwidth of 45 nm, and an A-scan-rate of 70 000 scans per second. Visible pathologic vessels were outlined manually on average intensity projection en face images, and the area of the lesion and the vessel density were measured at baseline and follow-up. RESULTS: At baseline, the neovascular lesion measured 4.12 mm(2) and the vessel density was 19.83 mm(-1). Four weeks after the first, and 2 and 4 weeks after the second ranibizumab injection, OCT angiography revealed a progressively smaller vascular lesion (2.32, 1.77 and 1.64 mm(2)), and vessel density (10.24, 8.52 and 7.57 mm(-1)), although the large central trunks of the lesion were unchanged. CONCLUSIONS: In this study, an obvious reduction in size and vessel density of the neovascular lesion was noted after treatment with ranibizumab using SSADA OCT angiography technology. Microvascular components can be delineated with precision, suggesting that this technique may be useful for the management of patients with neovascular AMD in a clinical setting as well as for future clinical trials.
PURPOSE: To study the precise structural aspects of a type 2 neovascular membrane in a patient with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography and perform sequential quantitative analysis of the membrane after ranibizumab therapy. PATIENTS AND METHODS: Split-spectrum amplitude-decorrelation (SSADA) OCT angiography macular cubes (3 × 3 mm) were acquired with a light source centered at 840 nm, a bandwidth of 45 nm, and an A-scan-rate of 70 000 scans per second. Visible pathologic vessels were outlined manually on average intensity projection en face images, and the area of the lesion and the vessel density were measured at baseline and follow-up. RESULTS: At baseline, the neovascular lesion measured 4.12 mm(2) and the vessel density was 19.83 mm(-1). Four weeks after the first, and 2 and 4 weeks after the second ranibizumab injection, OCT angiography revealed a progressively smaller vascular lesion (2.32, 1.77 and 1.64 mm(2)), and vessel density (10.24, 8.52 and 7.57 mm(-1)), although the large central trunks of the lesion were unchanged. CONCLUSIONS: In this study, an obvious reduction in size and vessel density of the neovascular lesion was noted after treatment with ranibizumab using SSADA OCT angiography technology. Microvascular components can be delineated with precision, suggesting that this technique may be useful for the management of patients with neovascular AMD in a clinical setting as well as for future clinical trials.
Authors: Yali Jia; Steven T Bailey; David J Wilson; Ou Tan; Michael L Klein; Christina J Flaxel; Benjamin Potsaid; Jonathan J Liu; Chen D Lu; Martin F Kraus; James G Fujimoto; David Huang Journal: Ophthalmology Date: 2014-03-27 Impact factor: 12.079
Authors: Eric Moult; WooJhon Choi; Nadia K Waheed; Mehreen Adhi; ByungKun Lee; Chen D Lu; Vijaysekhar Jayaraman; Benjamin Potsaid; Philip J Rosenfeld; Jay S Duker; James G Fujimoto Journal: Ophthalmic Surg Lasers Imaging Retina Date: 2014 Nov-Dec Impact factor: 1.300
Authors: Martin F Kraus; Benjamin Potsaid; Markus A Mayer; Ruediger Bock; Bernhard Baumann; Jonathan J Liu; Joachim Hornegger; James G Fujimoto Journal: Biomed Opt Express Date: 2012-05-03 Impact factor: 3.732
Authors: Yali Jia; Ou Tan; Jason Tokayer; Benjamin Potsaid; Yimin Wang; Jonathan J Liu; Martin F Kraus; Hrebesh Subhash; James G Fujimoto; Joachim Hornegger; David Huang Journal: Opt Express Date: 2012-02-13 Impact factor: 3.894
Authors: Martin F Kraus; Jonathan J Liu; Julia Schottenhamml; Chieh-Li Chen; Attila Budai; Lauren Branchini; Tony Ko; Hiroshi Ishikawa; Gadi Wollstein; Joel Schuman; Jay S Duker; James G Fujimoto; Joachim Hornegger Journal: Biomed Opt Express Date: 2014-07-11 Impact factor: 3.732
Authors: K Takayama; Y Ito; H Kaneko; K Kataoka; T Sugita; R Maruko; K Hattori; E Ra; F Haga; H Terasaki Journal: Eye (Lond) Date: 2016-11-04 Impact factor: 3.775
Authors: Vaël Souedan; Eric H Souied; Violaine Caillaux; Alexandra Miere; Ala El Ameen; Rocio Blanco-Garavito Journal: Int Ophthalmol Date: 2017-05-25 Impact factor: 2.031
Authors: Eiichi Hasegawa; Saori Inafuku; Lama Mulki; Yoko Okunuki; Ryoji Yanai; Kaylee E Smith; Clifford B Kim; Garrett Klokman; Diane R Bielenberg; Narender Puli; John R Falck; Deeba Husain; Joan W Miller; Matthew L Edin; Darryl C Zeldin; Kin Sing Stephen Lee; Bruce D Hammock; Wolf-Hagen Schunck; Kip M Connor Journal: Proc Natl Acad Sci U S A Date: 2017-08-21 Impact factor: 11.205
Authors: Carl B Rebhun; Eric M Moult; Stefan B Ploner; Carlos Moreira Neto; A Yasin Alibhai; Julia Schottenhamml; Byungkun Lee; WooJhon Choi; Fareed A Rifai; Mary W Tam; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Philip J Rosenfeld; Jay S Duker; James G Fujimoto; Nadia K Waheed Journal: Ophthalmol Retina Date: 2017-10-31
Authors: Rachel C Patel; Simon S Gao; Miao Zhang; Talal Alabduljalil; Abdullah Al-Qahtani; Richard G Weleber; Paul Yang; Yali Jia; David Huang; Mark E Pennesi Journal: Retina Date: 2016-12 Impact factor: 4.256